ALIVUS

Alivus Life Sciences Share Price

 

 

Alivus Life Sciences live price: ₹1044.25. It opened at ₹1,055 vs previous close ₹1,040; intraday high/low: ₹1,055/₹1,011. The 50 & 200 DMA stand at ₹943.83/₹945.36.

Alivus Life Sciences Performance

  • Today's Low
  • ₹1,011
  • Today's High
  • ₹1,055
  • 52 Week Low
  • ₹819
  • 52 Week High
  • ₹1,225
  • Open Price₹1,055
  • Previous Close₹1,040
  • Volume104,399
  • 50 DMA₹943.83
  • 100 DMA₹934.36
  • 200 DMA₹945.36

Investment Returns

  • Over 1 Month + 14.12%
  • Over 3 Month + 13.47%
  • Over 6 Month + 12.82%
  • Over 1 Year + 7.31%

Smart Investing Starts Here Start SIP with Alivus Life Sciences for Steady Growth!

Invest Now

Alivus Life Sciences Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 23.6
  • PEG Ratio
  • 1
  • Market Cap Cr
  • 12,817
  • P/B Ratio
  • 4
  • Average True Range
  • 37.89
  • EPS
  • 45.82
  • Dividend Yield
  • 0.5
  • MACD Signal
  • 18.23
  • RSI
  • 73.8
  • MFI
  • 81.56

Alivus Life Sciences Financials

Alivus Life Sciences Technicals

EMA & SMA

Current Price
₹1,044.25
+ 4.45 (0.43%)
pointer
  • Bearish Moving Average 0
  • Bullish Moving Average 16
  • 20 Day
  • ₹972.82
  • 50 Day
  • ₹943.83
  • 100 Day
  • ₹934.36
  • 200 Day
  • ₹945.36

Resistance and Support

1036.6 Pivot Speed
  • R3 1,106.80
  • R2 1,080.85
  • R1 1,062.55
  • S1 1,018.30
  • S2 992.35
  • S3 974.05

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Glenmark Life Sciences develops and manufactures high-quality Active Pharmaceutical Ingredients (APIs), supplying over 130 molecules to more than 700 global pharmaceutical companies. With world-class manufacturing and research capabilities, GLS focuses on operational excellence, regulatory compliance, and innovation.

Alivus Life Sciences Limited has an operating revenue of Rs. 2,512.26 Cr. on a trailing 12-month basis. An annual revenue growth of 5% is not great, Pre-tax margin of 27% is great, ROE of 17% is exceptional. The company is debt free and has a strong balance sheet enabling it to report stable earnings growth across business cycles. The stock from a technical standpoint is comfortably placed above its key moving averages, around 11% and 10% from 50DMA and 200DMA. From an O'Neil Methodology perspective, the stock has an EPS Rank of 69 which is a FAIR score but needs to improve its earnings, a RS Rating of 84 which is GOOD indicating the outperformance as compared to other stocks, Buyer Demand at A- which is evident from recent demand for the stock, Group Rank of 29 indicates it belongs to a strong industry group of Medical-Ethical Drugs and a Master Score of B is close to being the best. Overall, the stock is lagging behind in earnings parameter, but excellent technical strength makes it a stock to examine in more detail.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Alivus Life Sciences Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2026-01-22 Quarterly Results
2025-11-06 Quarterly Results
2025-08-01 Quarterly Results
2025-05-15 Audited Results & Final Dividend
2025-01-23 Quarterly Results
Date Purpose Remarks
2025-09-01 FINAL Rs.5.00 per share(250%)Final Dividend
2023-10-17 INTERIM Rs.22.50 per share(1125%)Interim Dividend
2023-03-24 INTERIM Rs.21.00 per share(1050%)Interim Dividend
2021-11-23 INTERIM Rs.10.50 per share(525%)Interim Dividend
View Alivus Life Sciences Dividend History Arrow

Alivus Life Sciences F&O

Alivus Life Sciences Shareholding Pattern

74.91%
5.44%
0.27%
5.08%
0%
10.21%
4.09%

Alivus Life Sciences FAQs

Alivus Life Sciences share price is ₹1,044 As on 09 April, 2026 | 02:54

The Market Cap of Alivus Life Sciences is ₹12816.7 Cr As on 09 April, 2026 | 02:54

The P/E ratio of Alivus Life Sciences is 23.6 As on 09 April, 2026 | 02:54

The PB ratio of Alivus Life Sciences is 4 As on 09 April, 2026 | 02:54

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23